Michael P. Brown

18.7k citations

279 papers · 13.1k indexed · 5 hit papers · h-index 50

Impact in

Oncology top 0.2%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Cytokine Signaling Pathways and Interactions
Immunology top 0.5%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction

Papers in

Oncology 124
- CAR-T cell therapy research 30
- Metal complexes synthesis and properties 24
- Cancer Immunotherapy and Biomarkers 24
Immunology 58
- Immunotherapy and Immune Responses 35
- Immune Cell Function and Interaction 29

Co-authors: Tessa Gargett David Haussler Alexander H. Staudacher Manuel Ares Nello Cristianini Charles W. Sugnet William Noble Grundy David Lin
Journals: Journal of Clinical Oncology (18 papers)Blood (12 papers)Clinical Cancer Research (7 papers)Inorganica Chimica Acta (7 papers)Journal of Organometallic Chemistry (6 papers)
Partner nations: Australia United States United Kingdom

In The Last Decade

Michael P. Brown

275 papers receiving 12.7k citations

Hit Papers

5 papers align trajectories log scale

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study 2018 · 655 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2018 The Lancet Oncology
2017 British Journal of Cancer
2012 The Lancet
2000 Proceedings of the National Academy of Sciences
1998 Cell

Peers

Countries citing papers authored by Michael P. Brown

Since Specialization

Citations

This map shows the geographic impact of Michael P. Brown's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael P. Brown with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael P. Brown more than expected).

Fields of papers citing papers by Michael P. Brown

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael P. Brown. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael P. Brown. The network helps show where Michael P. Brown may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael P. Brown, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael P. Brown Line = papers co-authored together Michael P. Brown links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Automating cancer registries: Pearls and pitfalls Health Information Management Journal ·刚邓, José Suárez González, Mariam Khalifa AlZaabi, Brandon Stretton, A. S. Purewal, Aashray Gupta, K Nasla., Karolina Luká, Theodore D. Thorton, Linda Herkenhoff, Martha Mozo-Barrero, 侯盈禎, WengOnn Chan, Michael J. Sorich, Michael P. Brown, Rosalind L. Jeffree, Stephen Bacchi	2025	0
2	Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma Frontiers in Immunology ·John Blalack, Tessa Gargett, Michael P. Brown, Lisa M. Ebert	2023	11
3	Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy Frontiers in Immunology ·A. Bean, V. Gold, Gege Xu, 隆則広瀬, Rachel Rice, Yana G. Najjar, Joseph Markowitz, Lisa M. Ebert, Michael P. Brown, Gonzalo Tapia Rico, Dennie T. Frederick, Afaf Nasser Sauh Shawaqfeh Afaf Nasser Sauh Shawaqfeh, Daniel Serie, Klaus Lindpaintner, Flavio Schwarz, Genevieve M. Boland	2023	9
4	An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer Journal for ImmunoTherapy of Cancer ·María Guadalupe Zavala Silva, Alexander H. Staudacher, Vasilios Liapis, Pina M. Cardarelli, G. SHIMAOKA, Michael P. Brown	2023	20
5	GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma Journal for ImmunoTherapy of Cancer ·Tessa Gargett, Lisa M. Ebert, Nga Truong, Matthew C. Rosen, 鈴木天之, Wenbo Yu, Saleh Afandiyev Saleh Afandiyev, María Guadalupe Zavala Silva, Briony L. Gliddon, Melinda N. Tea, Rebecca J. Ormsby, Santosh Poonnoose, Huamán Dolorier, Orazio Vittorio, David S. Ziegler, Stuart M. Pitson, Michael P. Brown	2022	72
6	Characteristic differences in radiation‐inducedDNAdamage response in human papillomavirus‐negative and human papillomavirus‐positive head and neck cancers with accumulation of fractional radiation dose Head & Neck ·Yanlan Mo, Alexander H. Staudacher, Loredana G. Marcu, Ian Olver, Tinatin Sydykova, Michael P. Brown, Eva Bezak	2021	1
7	APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo Molecular Cancer Therapeutics ·Alexander H. Staudacher, Yanrui Li, Vasilios Liapis, Triyulianto, David Y. Chin, Olan Dolezal, Timothy E. Adams, Patrick H. van Berkel, Michael P. Brown	2018	15
8	Experimental investigation of radiobiology in head and neck cancer cell lines as a function of HPV status, by MTT assay Scientific Reports ·Yanlan Mo, Puthenparampil Wilson, Yanrui Li, Loredana G. Marcu, Alexander H. Staudacher, Michael P. Brown, Eva Bezak	2018	9
9	In vitro investigation of head and neck cancer stem cell proportions and their changes following X-ray irradiation as a function of HPV status PLoS ONE ·Yanlan Mo, Puthenparampil Wilson, Yanrui Li, Loredana G. Marcu, Alexander H. Staudacher, Michael P. Brown, Eva Bezak	2017	19
10	Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma Clinical Cancer Research ·Fares Al‐Ejeh, Marina Pajic, Wei Shi, Murugan Kalimutho, Mariska Miranda, Adnan Nagrial, Angela Chou, Andrew V. Biankin, Sean M. Grimmond, (unknown), Michael P. Brown, Kum Kum Khanna	2014	31
11	Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436) Clinical Cancer Research ·Gerald S. Falchook, Georgina V. Long, Razelle Kurzrock, Maryam Khalid & Ramatu Muhammad Maiwada, James Winkelhoch, Michael P. Brown, Omid Hamid, Jeffrey R. Infante, Michael Millward, Anna C. Pavlick, Melvin Chin, Steven O’Day, Samuel C. Blackman, C. Martin Curtis, Peter F. Lebowitz, Bo Ma, Danièle Ouellet, Richard Kefford	2014	51
12	Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436) Clinical Cancer Research ·Katherine L. Nathanson, Anne‐Marie Martin, Bradley Wubbenhorst, Joel Greshock, Richard Letrero, Kurt D’Andrea, Steven O’Day, Jeffrey R. Infante, Gerald S. Falchook, Hendrik‐Tobias Arkenau, Michael Millward, Michael P. Brown, Anna C. Pavlick, Michael A. Davies, Bo Ma, Robert Gagnon, Jerome Stanley Rogers, Peter F. Lebowitz, Richard Kefford, Georgina V. Long	2013	132
13	Nutlin-3a Efficacy in Sarcoma Predicted by Transcriptomic and Epigenetic Profiling Cancer Research ·Kathleen I. Pishas, Susan J. Neuhaus, Mark Clayer, Andreas Schreiber, David Lawrence, Michelle Perugini, M. Kato, Gelareh Farshid, Jim Manavis, Steve Chryssidis, Bronwen J. Mayo, Ozair Alam, B. Jacobs, Michael P. Brown, Richard J. D’Andrea, Andreas Evdokiou, David M. Thomas, Jayesh Desai, David F. Callen, Paul M. Neilsen	2013	22
14	Targeted therapies, aspects of pharmaceutical and oncological management Adelaide Research & Scholarship (AR&S) (University of Adelaide) ·Michael P. Brown, W. Gradl	2013	3
15	Breast cancer stem cells: treatment resistance and therapeutic opportunities Carcinogenesis ·Fares Al‐Ejeh, Chanel E. Smart, Brian J. Morrison, Georgia Chenevix‐Trench, J. Alejandro López, Sunil R. Lakhani, Michael P. Brown, Kum Kum Khanna	2011	103
16	Nutlin-3a Is a Potential Therapeutic for Ewing Sarcoma Clinical Cancer Research ·Kathleen I. Pishas, Fares Al‐Ejeh, Irene Zinonos, Raman Kumar, Andreas Evdokiou, Michael P. Brown, David F. Callen, Paul M. Neilsen	2010	59
17	Transforming growth factor-β-mediated signaling in T lymphocytes impacts on prostate-specific immunity and early prostate tumor progression Laboratory Investigation ·Kerrilyn R. Diener, Anthony E. Woods, Jim Manavis, Michael P. Brown, John D. Hayball	2008	14
18	CD40 Ligand (CD154) Enhances the Th1 and Antibody Responses to Respiratory Syncytial Virus in the BALB/c Mouse The Journal of Immunology ·Ralph A. Tripp, Les Jones, Larry J. Anderson, Michael P. Brown	2000	47
19	MULTICULTURAL TRAINING FOR POLICE: A NATIONAL SURVEY. Michael P. Brown, J. V. F. SILVA	1995	2
20	STOCHASTIC CONTEXT-FREE GRAMMARS FOR MODELLING RNA Hawaii International Conference on System Sciences ·Sueaki Okamoto, Michael P. Brown, Ciprian Tiprigan, Shahzad I. Mian, David Haussler	1993	23

About Michael P. Brown

Michael P. Brown is a scholar working on Oncology, Immunology, Organic Chemistry, Inorganic Chemistry and Radiology, Nuclear Medicine and Imaging, having authored 279 papers that have together received 13.1k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (35 papers), Organometallic Complex Synthesis and Catalysis (35 papers), CAR-T cell therapy research (30 papers), Immune Cell Function and Interaction (29 papers), Metal complexes synthesis and properties (24 papers), Cancer Immunotherapy and Biomarkers (24 papers), Melanoma and MAPK Pathways (17 papers) and Radiopharmaceutical Chemistry and Applications (16 papers). The work is most often cited by research in Oncology (5.6k citations), Immunology (2.5k citations), Genetics (833 citations), Molecular Biology (5.2k citations) and Pulmonary and Respiratory Medicine (1.8k citations). Michael P. Brown has collaborated with scholars based in Australia, United States and United Kingdom. Frequent co-authors include Tessa Gargett, David Haussler, Alexander H. Staudacher, Manuel Ares, Nello Cristianini, Charles W. Sugnet, William Noble Grundy, David Lin, Terrence S. Furey and Richard J. Puddephatt. Their work appears in journals such as Journal of Clinical Oncology, Blood, Clinical Cancer Research, Inorganica Chimica Acta and Journal of Organometallic Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact